NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Healthcare Conference

By September 9, 2014

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that Ron Najafi, Ph.D., Chairman and CEO, will present a company update at the Rodman & Renshaw Healthcare Conference, held September 8-10, 2014 in New York City. Dr. Najafi along with Tom Paulson, Chief Financial Officer will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.

Event: Rodman & Renshaw 16th Annual Healthcare Conference
Date: Tuesday, September 9, 2014
Time: 3:45 PM (ET)
Place: New York Palace Hotel
Room: Kennedy Salon (4th floor)

To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay’s website at http://novabay.com/investors/events. A replay of the webcast will be available one hour after the conclusion of the live event.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its Hypochlorous Solution Family of FDA cleared commercial stage products: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™ for the dermatology market.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For Investor Inquiries, please contact:
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

 

TOP